SPOTLIGHT -
Dr. Fernandez on the Utility of Trastuzumab Deruxtecan in HER2-Low Breast Cancer
Aileen I. Fernandez, PhD, discusses the utility of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.
Read More
Dr. Fernandez on the Need to Refine Immunohistochemistry Testing in HER2+ Breast Cancer
Aileen I. Fernandez, PhD, discusses the need to refine immunohistochemistry testing in HER2-positive breast cancer.
Dr. Fernandez on the Results of a Study Examining Low HER2 Expression in Breast Cancer
Aileen I. Fernandez, PhD, discusses the results of a study examining low HER2 expression in breast cancer.
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
Better Understanding of Biomarkers Can Inform Immunotherapy Treatment in SCLC
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
